Voyager Therapeutics (NASDAQ:VYGR) Research Coverage Started at Wedbush

Wedbush assumed coverage on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research report released on Friday morning, Marketbeat reports. The brokerage issued an outperform rating and a $11.00 target price on the stock.

A number of other brokerages have also commented on VYGR. Leerink Partnrs raised Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. Canaccord Genuity Group reiterated a “buy” rating and set a $14.00 target price on shares of Voyager Therapeutics in a research report on Thursday, November 14th. StockNews.com raised shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, November 18th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Finally, Leerink Partners began coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price target on the stock. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Voyager Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $17.50.

Voyager Therapeutics Trading Up 18.7 %

Shares of NASDAQ:VYGR opened at $6.86 on Friday. The firm has a 50 day moving average of $6.51 and a 200-day moving average of $7.29. The stock has a market capitalization of $374.76 million, a PE ratio of 9.66 and a beta of 0.89. Voyager Therapeutics has a 12 month low of $5.19 and a 12 month high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The company had revenue of $24.63 million during the quarter, compared to analysts’ expectations of $12.63 million. During the same quarter in the previous year, the firm earned ($0.59) EPS. On average, research analysts predict that Voyager Therapeutics will post -0.92 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total transaction of $34,914.18. Following the completion of the sale, the insider now directly owns 86,001 shares of the company’s stock, valued at $500,525.82. This trade represents a 6.52 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 4.53% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Voyager Therapeutics

Several large investors have recently modified their holdings of VYGR. China Universal Asset Management Co. Ltd. increased its holdings in Voyager Therapeutics by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock worth $61,000 after acquiring an additional 4,098 shares during the last quarter. Intech Investment Management LLC bought a new position in Voyager Therapeutics during the third quarter worth about $74,000. SG Americas Securities LLC purchased a new position in shares of Voyager Therapeutics in the second quarter worth about $85,000. Victory Capital Management Inc. increased its stake in shares of Voyager Therapeutics by 14.5% in the second quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock worth $102,000 after purchasing an additional 1,630 shares in the last quarter. Finally, Hsbc Holdings PLC bought a new stake in shares of Voyager Therapeutics in the second quarter valued at approximately $128,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.